Conference Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

What to Expect at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

The inaugural RAVE conference begins today in Chicago, Illinois.

Spotlighting Vitiligo: New Innovations to be Presented at RAVE 2024

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.

A RAVE Upgrade: Previewing Revolutionizing Alopecia Areata, Vitiligo, and Eczema

Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.

Serum CXCL10 Levels Decreased With Use of Ruxolitinib Cream In Patients With Vitiligo

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Considerations for Topical Therapeutics and Clinical Excellence in Vitiligo

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Ritlecitinib Shows Promising Results in Long-Term Trial

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

Upadacitinib Demonstrates Continued Improvements in Patients With Moderate to Severe AD Through 140 Weeks

Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.

Don’t Forget to Address Autoimmune Comorbidities of Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

What’s New in Devices for Vitiligo?

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Day 1 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Safety vs Efficacy: What AD Treatments Can Be Used in Pediatric Patients?

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Comparing AD Guidelines From Around the World

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Exploring New Pathways in Atopic Dermatitis

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Looking Ahead to Advancements in Vitiligo and Atopic Dermatitis

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Addressing Itch and Remission in Atopic Dermatitis

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Late-Breaker: Upadacitinib Demonstrates Superiority Over Dupilumab in All Ranked Secondary End Points of Head-to-Head AD Study

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Prioritizing Itch and Sleep Improvement in Atopic Dermatitis

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Battle of the Two Titans: When to Progress AD Patients to Systemic Therapy

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC debated which patients are a contender for systemic therapy.

Day 2 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.